VentureBeat

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

Pre-screening study BASECAMP-1, is actively enrolling patients whose tumors have permanently lost HLA-A*02 AGOURA HILLS, Calif.–(BUSINESS WIRE)–November 7, 2022– A2 Biotherapeutics, Inc., “A2 Bio”, is ...
EurekAlert!

Scientists identify solid electrolyte materials that boost lithium-ion battery performance

image: The discovery by Evan Reed, associate professor of Materials Science & Engineering at Stanford, and visiting scholar Austin Sendek could help battery researchers design the first solid ...
Seeking Alpha

Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA

Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps identify solid tumour patients, including endometrial cancer patients, for treatment with Merck's immunotherapy KEYTRUDA.
Business Wire

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022

AGOURA HILLS, Calif.--(BUSINESS WIRE)--A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of first-in-class T cell therapeutics to tackle the fundamental ...